Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Significance: A better mechanistic understanding of the survival benefits and identification of biomarkers of response would greatly enhance the optimal utilization of antiangiogenic agents such as bevacizumab in combination with chemotherapy in the treatment of cancer. This study indicates that the benefits of bevacizumab with chemotherapy in non–small cell lung cancer (NSCLC) patients may depend on tumor vascular function during treatment. These correlative studies also provide new insights into the selection of NSCLC patients most likely to benefit from the addition of bevacizumab treatment to chemotherapy. The imaging and circulating biomarker candidates should be further evaluated in larger studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results suggest that high-dose anti-VEGF therapy limits the benefits of chemotherapy in mouse models and in patients with metastatic colorectal cancer (CRC) or advanced-stage NSCLC37,70,71”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [71]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309 · cited 1×
“carboplatin, nab-paclitaxel, and bevacizumab, with carboplatin given at a target area under the curve of 6 using the Cockroft–Gault equation (29) on day 1, nab-paclitaxel 100 mg/m(2) on days 1, 8, and 15, and bevacizumab 15 mg/kg on day 1 of every 21-d cycle.”
MethodPeto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Self-citationMolecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Self-citationWillett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966 · cited 4×
“SUVmean and SUVmax (31) using 18FDG-PET were also obtained at baseline and before cycles 3 and 5 of combination therapy.”
MethodInfluentialSelf-citationNormalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605 · cited 1×
“” Proceedings of the National Academy of Sciences 112 (5): 1547–52.”
BackgroundSelf-citationAntiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589 · cited 5×
“Int J Radiat Oncol Biol Phys 81(4):1081–1090.”
BackgroundResultInfluentialSelf-citationGaron, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309 · cited 1×
“This progress included the successful development of antiangiogenic drugs such as bevacizumab or ramucirumab in combination with chemotherapy (1, 2).”
BackgroundNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
Self-citationAnti-Angiogenesis: New Concept for Therapy of Solid Tumors
Folkman, J. (1972) · Annals of Surgery · doi:10.1097/00000658-197203000-00014 · Cited by 1,171 · cited 1×
“Originally, it was hypothesized that antiangiogenic agents would effectively starve the tumor of oxygen and nutrients by pruning the blood vessel system and reducing blood perfusion to tumors (3).”
BackgroundChauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101 · cited 1×
“Moreover, preclinical studies have demonstrated that lower doses of antiangiogenics may lead to improved drug distribution and reprogramming of the immune microenvironment toward an antitumor phenotype (19, 20).”
BackgroundSelf-citationHuang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099 · cited 1×
“Moreover, preclinical studies have demonstrated that lower doses of antiangiogenics may lead to improved drug distribution and reprogramming of the immune microenvironment toward an antitumor phenotype (19, 20).”
BackgroundSelf-citationSocinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Zhang, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5848 · Cited by 756 · cited 1×
“Furthermore, although the carboplatin and albumin-bound paclitaxel (nab-paclitaxel) regimen has shown superiority in response rate over carboplatin and paclitaxel in a large phase III study (10) leading to its approval for NSCLC patients, the addition of bevacizumab to this regimen is yet to be thoroughly tested.”
BackgroundReck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq020 · Cited by 638
Schneider, B. P., Wang, M., Radovich, M., Sledge, G. W., Badve, S., Thor, A., Flockhart, D. A., Hancock, B., Davidson, N., Gralow, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1612 · Cited by 604
Biomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
Self-citationBatchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3988 · Cited by 520
Self-citationZhu, A. X., Sahani, D. V., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Catalano, O. A., Sindhwani, V., Blaszkowsky, L. S., Yoon, S. S., Lahdenranta, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9908 · Cited by 477
Self-citationImplementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
Sequist, L. V., Heist, R. S., Shaw, A. T., Fidias, P., Rosovsky, R., Temel, J. S., Lennes, I. T., Digumarthy, S., Waltman, B. A., Bast, E., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr489 · Cited by 370 · cited 1×
“When available, tumors were tested for molecular alterations using the SNaPshot genotyping platform (30), a validated, Clinical Laboratory Improvement Amendments (CLIA)-approved multiplexed tumor genotyping assay that is used for real-time testing of tumors.”
MethodSelf-citationPatel, J. D., Socinski, M. A., Garon, E. B., Reynolds, C. H., Spigel, D. R., Olsen, M. R., Hermann, R. C., Jotte, R. M., Beck, T., Richards, D. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.9626 · Cited by 370 · cited 1×
“Efforts to improve on the outcomes have included combining bevacizumab with other agents, including carboplatin and pemetrexed (12), among others, but thus far, no regimen has shown clear superiority.”
BackgroundBatchelor, T. T., Gerstner, E. R., Emblem, K. E., Duda, D. G., Kalpathy-Cramer, J., Snuderl, M., Ancukiewicz, M., Polaskova, P., Pinho, M. C., Jennings, D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318022110 · Cited by 340
Self-citationVan der Veldt, A. A. M., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N. J. M., Hendrikse, N. H., Eriksson, J., Windhorst, A. D., Postmus, P. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.023 · Cited by 337 · cited 2×
“A previous study proposed that the mechanism of action of bevacizumab in NSCLC is reduction of chemotherapy uptake (9).”
BackgroundFalse discovery control with p-value weighting
Genovese, C. R., Roeder, K., & Wasserman, L. (2006) · Biometrika · doi:10.1093/biomet/93.3.509 · Cited by 320
Dahlberg, S. E., Sandler, A. B., Brahmer, J. R., Schiller, J. H., & Johnson, D. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4482 · Cited by 223
Zhu, A. X., Finn, R. S., Mulcahy, M., Gurtler, J., Sun, W., Schwartz, J. D., Dalal, R. P., Joshi, A., Hozak, R. R., Xu, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1442 · Cited by 159 · cited 1×
“Multiple previous studies have shown that high levels of sVEGFR1 are correlated with worse clinical outcomes, making sVEGFR1 a potential biomarker of intrinsic resistance to antiangiogenic therapy (22, 28).”
BackgroundSelf-citationPhase II Study of Neoadjuvant Bevacizumab and Radiotherapy for Resectable Soft Tissue Sarcomas
Yoon, S. S., Duda, D. G., Karl, D. L., Kim, T., Kambadakone, A. R., Chen, Y., Rothrock, C., Rosenberg, A. E., Nielsen, G. P., Kirsch, D. G., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.07.024 · Cited by 86
Self-citationCai, J., Ma, H., Huang, F., Zhu, D., Bi, J., Yang, K., & Zhang, T. (2013) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-11-306 · Cited by 85
Reynolds, C. H., Barrera, D., Jotte, R. M., Spira, A. I., Weissman, C., Boehm, K. A., Pritchard, S., & Asmar, L. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c0a2f4 · Cited by 60
Nab-Paclitaxel Is an Active Drug in Preclinical Model of Pediatric Solid Tumors
Zhang, L., Marrano, P. M., Kumar, S., Leadley, M., Elias, E., Thorner, P. S., & Baruchel, S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1485 · Cited by 60 · cited 1×
“In preclinical models, nab-paclitaxel has demonstrated higher drug concentration in tumors compared with solvent-based paclitaxel (11).”
BackgroundMeyerhardt, J. A., Ancukiewicz, M., Abrams, T. A., Schrag, D., Enzinger, P. C., Chan, J. A., Kulke, M. H., Wolpin, B. M., Goldstein, M., Blaszkowsky, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038231 · Cited by 48 · cited 1×
“Multiple previous studies have shown that high levels of sVEGFR1 are correlated with worse clinical outcomes, making sVEGFR1 a potential biomarker of intrinsic resistance to antiangiogenic therapy (22, 28).”
BackgroundSelf-citationRaut, C. P., Boucher, Y., Duda, D. G., Morgan, J. A., Quek, R., Ancukiewicz, M., Lahdenranta, J., Eder, J. P., Demetri, G. D., & Jain, R. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0026331 · Cited by 42
Self-citationGampenrieder, S. P., Romeder, F., Muß, C., Pircher, M., Ressler, S., Rinnerthaler, G., Bartsch, R., Sattlberger, C., Mlineritsch, B., & Greil, R. (2014) · PubMed · Cited by 42
Cited by
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Self-citationRethinking cancer nanotheranostics
Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.24 · Cited by 1,102
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 682
Self-citationAnti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017) · Angiogenesis · doi:10.1007/s10456-017-9552-y · Cited by 672
Self-citationTumour hypoxia causes DNA hypermethylation by reducing TET activity
Thienpont, B., Steinbacher, J., Zhao, H., D’Anna, F., Kuchnio, A., Ploumakis, A., Ghesquière, B., Van Dyck, L., Boeckx, B., Schoonjans, L., et al. (2016) · Nature · doi:10.1038/nature19081 · Cited by 635
Metadata
- Authors
- Heist, R. S., Duda, D. G., Sahani, D. V., Ancukiewicz, M., Fidias, P., Sequist, L. V., Temel, J. S., Shaw, A. T., Pennell, N. A., Neal, J. W., Gandhi, L., Lynch, T. J., Engelman, J. A., & Jain, R. K.
- Affiliations
- Departments of aMedicine,
- Radiation Oncology, and
- Harvard University (US)
- Department of Medical Oncology, University of Arizona Cancer Center at Dignity, Phoenix, AZ 85013;
- Cleveland Clinic (US)
- Stanford Cancer Institute (US)
- Dana-Farber Cancer Institute (US)
- Yale Cancer Center (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2015-01-20
- Volume
- 112
- Issue
- 5
- Pages
- 1547-1552
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4321320
- OpenAlex
- W1981486151
- Cited by
- 126
- References
- 34
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 9 · 2021: 12 · 2020: 13 · 2019: 11 · 2018: 17 · 2017: 25 · 2016: 16 · 2015: 12
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, other-oa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- HHS | NIH | National Cancer Institute (P01CA080124, R01CA159258)
- U.S. Department of Defense (W81XWH-10-1-0016)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- bevacizumab, anti-VEGF therapy, non-small cell lung cancer, carboplatin, nab-paclitaxel, tumor vascularization, vascular rarefaction, vascular permeability, placental growth factor, soluble VEGFR1, treatment resistance biomarkers, dynamic contrast-enhanced CT, plasma cytokines, progression-free survival, combination chemotherapy
- MeSH terms
- Bevacizumab, Albumins, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neovascularization, Pathologic, Biomarkers, Tumor, Carboplatin, Paclitaxel, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.